An orally active CSF-1R kinase inhibitor (BLZ945, 200 mg/kg), which readily passes through blood brain barrier, has been shown to specifically target macrophages depletion, enhance CD8+ T cell infiltration, and prevent tumor growth in the K14-HPV16 transgenic mouse model of cervical carcinoma [19]. Here, CD8A is linked to neoplasm.